Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia

Detalles Bibliográficos
Autores principales: Tadmor, Tamar, Benjamini, Ohad, Braester, Andrei, Rahav, Galia, Rokach, Lior
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353933/
https://www.ncbi.nlm.nih.gov/pubmed/34376803
http://dx.doi.org/10.1038/s41375-021-01380-5
_version_ 1783736503429496832
author Tadmor, Tamar
Benjamini, Ohad
Braester, Andrei
Rahav, Galia
Rokach, Lior
author_facet Tadmor, Tamar
Benjamini, Ohad
Braester, Andrei
Rahav, Galia
Rokach, Lior
author_sort Tadmor, Tamar
collection PubMed
description
format Online
Article
Text
id pubmed-8353933
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-83539332021-08-10 Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia Tadmor, Tamar Benjamini, Ohad Braester, Andrei Rahav, Galia Rokach, Lior Leukemia Correspondence Nature Publishing Group UK 2021-08-10 2021 /pmc/articles/PMC8353933/ /pubmed/34376803 http://dx.doi.org/10.1038/s41375-021-01380-5 Text en © The Author(s), under exclusive licence to Springer Nature Limited 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Correspondence
Tadmor, Tamar
Benjamini, Ohad
Braester, Andrei
Rahav, Galia
Rokach, Lior
Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title_full Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title_fullStr Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title_full_unstemmed Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title_short Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
title_sort antibody persistence 100 days following the second dose of bnt162b mrna covid19 vaccine in patients with chronic lymphocytic leukemia
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8353933/
https://www.ncbi.nlm.nih.gov/pubmed/34376803
http://dx.doi.org/10.1038/s41375-021-01380-5
work_keys_str_mv AT tadmortamar antibodypersistence100daysfollowingtheseconddoseofbnt162bmrnacovid19vaccineinpatientswithchroniclymphocyticleukemia
AT benjaminiohad antibodypersistence100daysfollowingtheseconddoseofbnt162bmrnacovid19vaccineinpatientswithchroniclymphocyticleukemia
AT braesterandrei antibodypersistence100daysfollowingtheseconddoseofbnt162bmrnacovid19vaccineinpatientswithchroniclymphocyticleukemia
AT rahavgalia antibodypersistence100daysfollowingtheseconddoseofbnt162bmrnacovid19vaccineinpatientswithchroniclymphocyticleukemia
AT rokachlior antibodypersistence100daysfollowingtheseconddoseofbnt162bmrnacovid19vaccineinpatientswithchroniclymphocyticleukemia

Ejemplares similares